Loews (L) Stock
Key stats
- Market cap
- $22.47B
- Price / Earnings ratio
- 15.2x
- EPS (TTM)
- $7.24
- Volume
- Loading
- 52-week high
- $121.01
- 52-week low
- $100.59
- Dividend yield
- 0.23%
- Dividend amount (latest)
- $0.06
Source: third-party data provider, as of November 7, 2026
Compare with L
Recent news

This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled
This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled
L

Hotels and pipelines drive Loews profits higher as insurance underwriting softens
Hotels and pipelines drive Loews profits higher as insurance underwriting softens
L

Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
L

Loews Corporation reports year-over-year drop in profit
Loews Corporation reports year-over-year drop in profit
L
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 54.75
- MACD 12/26/9
- 0.81
- EMA 9 of MACD
- 0.84
- MACD histogram
- -0.03
- SMA 50
- $108.65
- Price above SMA 50
- EMA 50
- $109.81
- Price above EMA 50
- SMA 200
- $109.56
- Price above SMA 200
- EMA 200
- $108.69
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market has no earnings per share expectations for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled
This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled
L

Hotels and pipelines drive Loews profits higher as insurance underwriting softens
Hotels and pipelines drive Loews profits higher as insurance underwriting softens
L

Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
L

Loews Corporation reports year-over-year drop in profit
Loews Corporation reports year-over-year drop in profit
L

Loews Corporation reports higher Q4 and full-year profit
Loews Corporation reports higher Q4 and full-year profit
L

Loews reports quarterly weakness on CNA's underwriting woes
Loews reports quarterly weakness on CNA's underwriting woes
L

Stop Sleeping on These 3 Stocks (Seriously)
Stop Sleeping on These 3 Stocks (Seriously)
L

The Big 3: CLX, AEP, L
The Big 3: CLX, AEP, L
L

Loews' quarterly profit rises on investment income, strong insurance unit
Loews' quarterly profit rises on investment income, strong insurance unit
L

Loews (L) Q2 EPS Jumps 12%
Loews (L) Q2 EPS Jumps 12%
L
News tone: automated (AI) classification of the article's content, not a price prediction.
About Loews
Loews Corporation is a diversified company, with businesses in the insurance, energy, hospitality and packaging industries. Our consolidated subsidiaries are: CNA Financial, Boardwalk Pipelines, Loews Hotels and Altium Packaging. Loews is focused on long-term value creation for its shareholders, and conservative financial management.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Benjamin J. Tisch | CEO, President & Director | 1983 |
| Ms. Jane J. Wang | Senior VP & CFO | 1982 |
| Mr. Kenneth I. Siegel | Senior Vice President | 1957 |
| Mr. Alexander H. Tisch | VP & Director | 1978 |
| Mr. David Eugene Czerniecki C.F.A. | Senior VP & Chief Investment Officer | 1965 |
| Mr. Mark S. Schwartz | VP, Chief Accounting Officer & Treasurer | — |
| Mr. Chris Nugent | VP of Investor Relations & Corporate Development | — |
| Mr. Marc A. Alpert J.D. | Senior VP, General Counsel & Corporate Secretary | 1963 |
| Mr. Ira Altman | Vice President of Human Resources | — |
| Mr. Peter W. Keegan | Senior Advisor to the President | 1945 |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 7, 2026
Technical indicators
- RSI 14
- 54.75
- MACD 12/26/9
- 0.81
- EMA 9 of MACD
- 0.84
- MACD histogram
- -0.03
- SMA 50
- $108.65
- Price above SMA 50
- EMA 50
- $109.81
- Price above EMA 50
- SMA 200
- $109.56
- Price above SMA 200
- EMA 200
- $108.69
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -7.9 | +8.1 | ||||||||||
| 2022 | +2.7 | +1.3 | +8.6 | -3.7 | +6.4 | -8.5 | -3.2 | -0.6 | -10.2 | +10.7 | +2.9 | +0.5 |
| 2023 | +4.9 | +0.9 | -5.3 | -0.0 | -6.9 | +5.3 | +4.9 | -1.4 | +1.6 | +2.7 | +7.9 | -0.6 |
| 2024 | +3.4 | +3.9 | +5.2 | -3.0 | +0.7 | -1.5 | +7.0 | +3.5 | -3.4 | -0.4 | +9.4 | -1.7 |
| 2025 | +1.5 | +1.6 | +5.5 | -5.7 | +3.5 | +2.2 | -1.9 | +7.2 | +4.3 | -0.6 | +8.5 | -1.0 |
| 2026 | +0.9 | +4.0 | -4.9 | +5.6 | -7.3 | +9.0 | +1.7 | -6.8 | -3.9 | +6.0 | -0.2 |
Corporate actions
Upcoming
No upcoming corporate actions for L




